Phreesia, Inc. (NYSE:PHR – Get Free Report) has received a consensus recommendation of “Hold” from the nineteen brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $14.00.
A number of brokerages have recently issued reports on PHR. Weiss Ratings downgraded shares of Phreesia from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 4th. Citigroup reissued a “market perform” rating on shares of Phreesia in a report on Friday, September 4th. Needham & Company LLC restated a “buy” rating and set a $14.00 price objective on shares of Phreesia in a research report on Monday, August 31st. Robert W. Baird increased their price objective on shares of Phreesia from $10.00 to $11.00 and gave the company a “neutral” rating in a research report on Friday, September 4th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $19.00 target price on shares of Phreesia in a report on Thursday, September 3rd.
View Our Latest Analysis on Phreesia
Hedge Funds Weigh In On Phreesia
Phreesia Trading Up 1.6%
Shares of NYSE:PHR opened at $10.34 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.76 and a quick ratio of 1.76. Phreesia has a 1 year low of $7.77 and a 1 year high of $25.29. The company has a market cap of $641.62 million, a P/E ratio of 60.81 and a beta of 0.86. The stock’s fifty day moving average price is $11.23 and its 200-day moving average price is $10.41.
Phreesia (NYSE:PHR – Get Free Report) last released its quarterly earnings data on Wednesday, September 2nd. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.06). Phreesia had a return on equity of 5.22% and a net margin of 2.06%.The business had revenue of $129.46 million during the quarter, compared to the consensus estimate of $129.06 million. During the same quarter in the previous year, the business posted $0.01 earnings per share. Phreesia’s quarterly revenue was up 10.4% compared to the same quarter last year. Sell-side analysts expect that Phreesia will post 0.33 earnings per share for the current year.
Phreesia Company Profile
Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.
Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.
Featured Articles
- Five stocks we like better than Phreesia
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.
